BrightPath Biotherapeutics Co

BrightPath Biotherapeutics Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightPath Biotherapeutics Co (4594.T) as of Oct 18, 2026 is -1.30 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.16 B JPY — a change of 11.55% (lower).

EBITDA

-1.30 BJPY

YoY

11.55%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightPath Biotherapeutics Co is 2026 -1.30 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightPath Biotherapeutics Co was 2025 -1.16 B JPY. It decreases by 11.55% lower compared to the previous year.

The BrightPath Biotherapeutics Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-1.69 B JPY
Jan 1, 2020
-1.83 B JPY
Jan 1, 2021
-1.73 B JPY
Jan 1, 2022
-1.48 B JPY
Jan 1, 2023
-1.48 B JPY
Jan 1, 2024
-1.16 B JPY
Jan 1, 2025
-1.16 B JPY
Jan 1, 2026
-1.30 B JPY
The BrightPath Biotherapeutics Co EBITDA history
YEAREBITDAYoY
-1.30 BJPY+11.55%
-1.16 BJPY+0.51%
-1.16 BJPY-22.15%
-1.48 BJPY+0.15%
-1.48 BJPY-14.51%
-1.73 BJPY-5.17%
-1.83 BJPY+7.91%
-1.69 BJPY+5.75%
-1.60 BJPY+44.21%
-1.11 BJPY+12.30%
-988.66 MJPY+100.91%
-492.09 MJPY+1,676.17%
-27.71 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BrightPath Biotherapeutics Co Stock analysis

What does BrightPath Biotherapeutics Co do? BrightPath Biotherapeutics Co Ltd, headquartered in Chiyoda-ku, Tokyo, operates in the Health Care sector, specializing in biotechnology. The company develops cancer peptide vaccines as part of cancer immunotherapy, focusing on drug discovery, early clinical development, and commercialization of immunotherapeutic drugs in Japan and internationally. It generates revenue through license fees from pharmaceutical companies. Listed on October 22, 2015, the firm employs 32 full-time staff. BrightPath Biotherapeutics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightPath Biotherapeutics Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightPath Biotherapeutics Co is -1.30 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BrightPath Biotherapeutics Co changed from -1.16 B JPY to -1.30 B JPY, representing a 11.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BrightPath Biotherapeutics Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BrightPath Biotherapeutics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — BrightPath Biotherapeutics Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BrightPath Biotherapeutics Co